These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

675 related articles for article (PubMed ID: 25326837)

  • 1. [Modulation of the incretin effect in the treatment of diabetes].
    Vidal J
    Med Clin (Barc); 2014; 143 Suppl 2():8-11. PubMed ID: 25326837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Modulation of the incretin effect in the treatment of diabetes].
    Vidal J
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():8-11. PubMed ID: 25437459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Characteristics and types of GLP-1 receptor agonists. An opportunity for individualized therapy].
    Jódar E
    Med Clin (Barc); 2014; 143 Suppl 2():12-7. PubMed ID: 25326838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B
    Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
    Dawwas GK; Smith SM; Park H
    Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
    Cornell S
    J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
    Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
    Escalada FJ
    Med Clin (Barc); 2014; 143 Suppl 2():2-7. PubMed ID: 25326836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incretin effect: GLP-1, GIP, DPP4.
    Kazafeos K
    Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S32-6. PubMed ID: 21864749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incretin-based therapy of type 2 diabetes mellitus.
    Knop FK; Vilsbøll T; Holst JJ
    Curr Protein Pept Sci; 2009 Feb; 10(1):46-55. PubMed ID: 19275672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on incretin hormones.
    Phillips LK; Prins JB
    Ann N Y Acad Sci; 2011 Dec; 1243():E55-74. PubMed ID: 22545749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in micro- and nanotechnologies for the GLP-1-based therapy and imaging of pancreatic beta-cells.
    Moonschi FH; Hughes CB; Mussman GM; Fowlkes JL; Richards CI; Popescu I
    Acta Diabetol; 2018 May; 55(5):405-418. PubMed ID: 29264724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretin-based therapies: where will we be 50 years from now?
    Meier JJ; Nauck MA
    Diabetologia; 2015 Aug; 58(8):1745-50. PubMed ID: 25994073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Characteristics and types of GLP-1 receptor agonists. An opportunity for individualized therapy].
    Jódar E
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():12-7. PubMed ID: 25437460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.
    Kirk RK; Pyke C; von Herrath MG; Hasselby JP; Pedersen L; Mortensen PG; Knudsen LB; Coppieters K
    Diabetes Obes Metab; 2017 May; 19(5):705-712. PubMed ID: 28094469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.